MKUL yields 3696.86% · PFE yields 6.20%● Live data
📍 MKUL pulled ahead of the other in Year 1
Combined, MKUL + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MKUL + PFE for your $10,000?
Molekule Group, Inc., an interior space air purification technology company, provides air purification solutions for hospitals and other healthcare facilities. The company offers interior air sterilization and disinfection products for the eradication of harmful airborne pathogens, including COVID-19. Its air hygiene product, Purgo (pure-go), a medical device that provides continuous air filtration, sanitization, and supplemental ventilation solutions with technology applied in any indoor space, including in hospitals, offices, and elevators. The company's Purgo products feature SteriDuct, a proprietary germicidal technology that work to equipment and devices to reduce the exposure of occupants of interior spaces to airborne particles and pathogens; Air Mini+, a direct-to-consumer air purifier, which features include a particle sensor, five fan speeds, and automatic fan speed adjustment through the product's auto protect mode; Air Pro, a direct-to-consumer and business-to-business product for rooms of up to 1,000 square feet; and Air Pro Rx, a medical-grade purifier designed for traffic areas in healthcare facilities for rooms more than 600 square feet. It also offers PECO-HEPA Tri-Power filter; Molekule App, a mobile application that provides a 28 day look back of IAQ trends sensed by the Air Pro air purifier, breaking down pollutants detected, including VOCs, and pollutants that range from PM 1 to PM 10 in size; and Molekule Air Platform, a dashboard that allows data from multiple air purifiers and controls to be accessed in one interface. The company was formerly known as AeroClean Technologies, Inc. and changed its name to Molekule Group, Inc. in January 2023. Molekule Group, Inc. was founded in 2011 and is headquartered in Palm Beach Gardens, Florida.
Full MKUL Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.